Direct-to-Consumer Teledermatology Growth: A Review and Outlook for the Future.
Journal
Cutis
ISSN: 2326-6929
Titre abrégé: Cutis
Pays: United States
ID NLM: 0006440
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
9
6
2022
Statut:
ppublish
Résumé
The direct-to-consumer (DTC) telemedicine industry, including teledermatology, has seen rapid expansion in recent years, partly because of the COVID-19 pandemic. The shortage of dermatologists and the visual nature of dermatologic conditions attracted DTC companies to dermatology. As more patients continue to seek medical consultations and prescription medications from these for-profit companies, we must approach their growth with healthy skepticism. Shortcomings of DTC teledermatology include concerns about conflicts of interest (COIs), overdiagnosis, and overprescribing. Although DTC teledermatology is certainly here to stay, an appropriate understanding of this industry will allow dermatologists to advise patients and advocate for best practices.
Identifiants
pubmed: 35659836
pii: cutis.0503
doi: 10.12788/cutis.0503
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM